Lexeo Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Lexeo Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Lexeo Therapeutics, Inc. Common Stock (LXEO) has a Cash Flow-to-Debt Ratio of -0.89x as of June 2026, meaning its operating cash flow of $-17.60 Million could theoretically repay -1% of its total liabilities ($19.84 Million) in one year. See LXEO FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Lexeo Therapeutics, Inc. Common Stock (2020–2025)
Cash flow-to-debt ratio of Lexeo Therapeutics, Inc. Common Stock from 2020 to 2025. Historical debt coverage capacity for Lexeo Therapeutics, Inc. Common Stock across 6 annual periods. Also explore net asset momentum of Lexeo Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Lexeo Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2020–2025)
Lexeo Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Lexeo Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see Lexeo Therapeutics, Inc. Common Stock (LXEO) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.48x | $-98.56 Million | $22.02 Million | ▼ -66.0% |
| 2024 | -2.70x | $-81.15 Million | $30.10 Million | ▼ -19.1% |
| 2023 | -2.26x | $-59.50 Million | $26.27 Million | ▼ -771.8% |
| 2022 | -0.26x | $-54.56 Million | $210.03 Million | ▼ -13.2% |
| 2021 | -0.23x | $-44.18 Million | $192.46 Million | ▼ -156.0% |
| 2020 | -0.09x | $-3.13 Million | $34.95 Million | — |